Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R de Wit

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 20, 2010
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxelM H Strijbos, J W Gratama, P I M Schmitz, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancerR J van Soest, M E van Royen, E S de Morrée, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2002
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerM M Borner, P Schoffski, R de Wit, et al.
British Journal of Cancer|July 2, 1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patientsR de Wit, W H Kruit, C H Lamers, et al.
British Journal of Cancer|April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patientsF E de Jongh, R N van Veen, S J Veltman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2015
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerR J van Soest, A J M Nieuweboer, E S de Morrée, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|April 20, 2010
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxelM H Strijbos, J W Gratama, P I M Schmitz, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancerR J van Soest, M E van Royen, E S de Morrée, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2002
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerM M Borner, P Schoffski, R de Wit, et al.
British Journal of Cancer|July 2, 1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patientsR de Wit, W H Kruit, C H Lamers, et al.
British Journal of Cancer|April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patientsF E de Jongh, R N van Veen, S J Veltman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2015
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerR J van Soest, A J M Nieuweboer, E S de Morrée, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
Pageof 15